ZA95786B - Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1 recombinant mage-1 and mage-1 derived immunogeni peptides - Google Patents

Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1 recombinant mage-1 and mage-1 derived immunogeni peptides

Info

Publication number
ZA95786B
ZA95786B ZA95786A ZA95786A ZA95786B ZA 95786 B ZA95786 B ZA 95786B ZA 95786 A ZA95786 A ZA 95786A ZA 95786 A ZA95786 A ZA 95786A ZA 95786 B ZA95786 B ZA 95786B
Authority
ZA
South Africa
Prior art keywords
mage
peptides
monoclonal antibodies
bind
immunogeni
Prior art date
Application number
ZA95786A
Other languages
English (en)
Inventor
Yao-Tsen Chen
Elisabeth Stockert
Yachi Chen
Pilar Garin-Chesa
Wolfgang J Rettig
Pierre Van Der Bruggen
Thierry Boon-Falleur
Lloyd J Old
Original Assignee
Ludwig Inst Cancer Res
Sloan Kettering Inst Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res, Sloan Kettering Inst Cancer filed Critical Ludwig Inst Cancer Res
Publication of ZA95786B publication Critical patent/ZA95786B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA95786A 1994-02-01 1995-02-01 Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1 recombinant mage-1 and mage-1 derived immunogeni peptides ZA95786B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/190,411 US5541104A (en) 1991-05-23 1994-02-01 Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1

Publications (1)

Publication Number Publication Date
ZA95786B true ZA95786B (en) 1995-10-09

Family

ID=22701236

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA95786A ZA95786B (en) 1994-02-01 1995-02-01 Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1 recombinant mage-1 and mage-1 derived immunogeni peptides

Country Status (16)

Country Link
US (2) US5541104A (xx)
EP (1) EP0752876B1 (xx)
JP (1) JPH09511389A (xx)
CN (1) CN1145032A (xx)
AT (1) ATE215831T1 (xx)
AU (1) AU686314B2 (xx)
CA (1) CA2182369A1 (xx)
DE (1) DE69526339T2 (xx)
DK (1) DK0752876T3 (xx)
ES (1) ES2174931T3 (xx)
FI (1) FI963033A0 (xx)
NO (1) NO963120L (xx)
NZ (1) NZ279377A (xx)
PT (1) PT752876E (xx)
WO (1) WO1995020974A1 (xx)
ZA (1) ZA95786B (xx)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925729A (en) * 1991-05-23 1999-07-20 Ludwig Institute For Cancer Research Tumor rejection antigen precursors, tumor rejection antigens and uses thereof
USRE40089E1 (en) * 1991-05-23 2008-02-19 Ludwig Institute For Cancer Research Nucleic acid molecules encoding the MAGE-1 tumor rejection antigen precursor
US6060257A (en) * 1994-06-03 2000-05-09 Ludwig Institute For Cancer Research Tumor rejection antigens presented by HLA-B44 molecules, and uses thereof
KR0185334B1 (ko) * 1995-11-02 1999-04-01 김은영 인간 혈장 아포지단백질 비-100에 결합하는 생쥐 항체를 암호하는 씨디엔에이
US5908778A (en) * 1996-10-03 1999-06-01 Ludwig Institute For Cancer Research Mage-10 encoding cDNA, the tumor rejection antigen precursor mage-10, antibodies specific to the molecule, and uses thereof
CA2309765A1 (en) * 1997-12-18 1999-06-24 G.D. Searle & Co. Venezuelan equine encephalitis virus vectors expressing tumor-associated antigens to induce cancer immunity
DK1659179T3 (da) 1998-02-05 2011-10-10 Glaxosmithkline Biolog Sa Tumor-associerede antigenderivater fra MAGE-familien og nucleinsyresekvenser kodende for dem anvendt til fremstilling af fusionsproteiner og sammensætninger til vaccination
US7157091B1 (en) 1999-06-18 2007-01-02 Ludwig Institute For Cancer Research MAGE-A1 peptides presented by HLA class II molecules
DK1282702T3 (da) 2000-05-10 2007-04-02 Sanofi Pasteur Ltd Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf
EP1377680B1 (en) 2001-04-12 2011-10-05 Imperial Innovations Limited Diagnosis and treatment of breast cancer based upon scn5a
US7786278B2 (en) 2002-04-09 2010-08-31 Sanofi Pasteur Limited Modified CEA nucleic acid and expression vectors
CN101124327A (zh) * 2003-10-08 2008-02-13 圣诺菲·帕斯图尔公司 经修饰的cea/b7载体
FR2889959A1 (fr) * 2005-09-01 2007-03-02 Commissariat Energie Atomique Epitopes t cd4+ des antigenes mage-a restreints a hla-dp4 et leurs applications
US8129184B2 (en) 2006-09-26 2012-03-06 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
CA2700436C (en) * 2006-09-28 2017-04-18 John S. Yu Cancer vaccines and vaccination methods
DK2328923T3 (en) 2008-09-02 2016-03-21 Cedars Sinai Medical Center CD133 epitopes
US9175070B2 (en) 2009-09-25 2015-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to HIV-1 and their use
GB201120860D0 (en) 2011-12-05 2012-01-18 Cambridge Entpr Ltd Cancer immunotherapy
WO2014127296A1 (en) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd Cancer vaccines and vaccination methods
WO2016094309A1 (en) 2014-12-10 2016-06-16 Myosotis Inhibition of tnf signaling in cancer immunotherapy
EP3943098A3 (en) 2015-07-16 2022-05-11 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
GB201519340D0 (en) 2015-11-02 2015-12-16 Cambridge Entpr Ltd Methods of T-lymphocyte expansion
GB201519481D0 (en) 2015-11-04 2015-12-16 Cancer Rec Tech Ltd Immunomodulatory antibodies
GB201616238D0 (en) 2016-09-23 2016-11-09 Adaptimmune Ltd Modified T cells
HRP20230937T1 (hr) 2017-01-05 2023-11-24 Kahr Medical Ltd. Pd1-41bbl fuzijski protein i metode korištenja istog
ES2916217T3 (es) 2017-01-05 2022-06-29 Kahr Medical Ltd Una proteína de fusión SIRP1 ALPHA-41BBL y métodos de uso de la misma
GB201700345D0 (en) 2017-01-09 2017-02-22 F-Star Beta Ltd Conditional agonists of immune responses
IL250916A0 (en) 2017-03-02 2017-06-29 Geiger Benjamin Methods for growing t cells in culture and their use
WO2019006003A1 (en) 2017-06-27 2019-01-03 The Trustees Of Princeton University COMPOSITIONS AND METHODS FOR IMPROVING IMMUNOTHERAPY
GB201713078D0 (en) 2017-08-15 2017-09-27 Adaptimmune Ltd T Cell Modification
US20210052695A1 (en) 2018-01-26 2021-02-25 Cambridge Enterprise Limited Peptide exchange protein
EP3814385A4 (en) 2018-07-11 2022-04-06 KAHR Medical Ltd. SIRPALPHA-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
US20210379109A1 (en) 2018-08-24 2021-12-09 The Trustees Of Princeton University Immunotherapy with metabolic enzyme expression
GB201820444D0 (en) 2018-12-14 2019-01-30 Adaptimmune Ltd Marker for T cell expansion
AU2020311636A1 (en) 2019-07-11 2022-03-03 Kahr Medical Ltd. Heterodimers and methods of use thereof
GB201911954D0 (en) 2019-08-20 2019-10-02 Adaptimmune Ltd Lentiviral transduction methods
WO2021137230A1 (en) 2019-12-31 2021-07-08 Kahr Medical Ltd. Methods of culturing t cells and uses of same
US20230048719A1 (en) 2019-12-31 2023-02-16 Kahr Medical Ltd. Methods of culturing t cells with a 4-1bbl fusion polypeptide and uses of same
IL276599A (en) 2020-08-09 2022-03-01 Yeda Res & Dev T cell receptor unique to mage-a1 and its uses
WO2023083864A1 (en) 2021-11-09 2023-05-19 T-Knife Gmbh Methods of selecting a patient for treatment of a mage-a1 positive solid tumor, of predicting whether a patient being diagnosed with mage-a1 positive solid tumor will be responsive to treatment of this tumor and of treating a patient being diagnosed with such a mage-a1 positive solid tumor as well as corresponding pharmaceutical compositions and diagnostic kits

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
KR950003005B1 (ko) * 1992-04-09 1995-03-29 주식회사 진흥전자 자동소변세척기
DE4224542A1 (de) * 1992-07-24 1994-01-27 Deutsches Krebsforsch Verfahren zur Herstellung von monoklonalen MHC Klasse I-puls-Peptid-restringierten Antikörpern

Also Published As

Publication number Publication date
JPH09511389A (ja) 1997-11-18
EP0752876B1 (en) 2002-04-10
NO963120D0 (no) 1996-07-26
FI963033A (fi) 1996-07-31
WO1995020974A1 (en) 1995-08-10
EP0752876A4 (en) 1999-07-07
US5843448A (en) 1998-12-01
NO963120L (no) 1996-09-30
US5541104A (en) 1996-07-30
CA2182369A1 (en) 1995-08-10
CN1145032A (zh) 1997-03-12
AU1597995A (en) 1995-08-21
PT752876E (pt) 2002-09-30
ATE215831T1 (de) 2002-04-15
DE69526339T2 (de) 2003-01-02
DE69526339D1 (de) 2002-05-16
ES2174931T3 (es) 2002-11-16
AU686314B2 (en) 1998-02-05
FI963033A0 (fi) 1996-07-31
DK0752876T3 (da) 2002-05-21
EP0752876A1 (en) 1997-01-15
NZ279377A (en) 1997-07-27

Similar Documents

Publication Publication Date Title
ZA95786B (en) Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1 recombinant mage-1 and mage-1 derived immunogeni peptides
EP0939653A4 (en) Humanization of anti-carcinoembryonic antigen anti-idiotypic antibodies and its use as a tumor vaccine and for labeling
ZA945364B (en) Antibodies specific for human prostate glandular kallikrein
SI0970126T1 (en) Novel method for the production of antihuman antigen receptors and uses thereof
UA40577C2 (uk) Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
EP0394277A4 (en) Second generation monoclonal antibodies having binding specificity to tag-72 and human carcinomas and methods for employing the same
CA2149120A1 (en) Monoclonal antibody which specifically binds to tumor vascular endothelium and uses thereof
FI963780A (fi) Kasvainhyljintäantigeeniprekursorista MAGE-2 saatuja eristettyjä peptidejä ja niiden käyttöjä
NZ296564A (en) Method of improving antigenicity of antigens or haptens, fusion with rsv peptides; vaccines, vectors, nucleotides
WO1998022510A3 (en) Methods for the production of chicken monoclonal antibodies
DE69511399D1 (de) Isolierte, von mage-3 abgeleitete peptide, welche mit hla-a2 molekülen komplexieren
OA09802A (en) Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus.
EP0784684B8 (en) RECOMBINANT PEPTIDES DERIVED FROM THE Mc3 ANTI-BA46 ANTIBODY, METHODS OF USE THEREOF, AND METHODS OF HUMANIZING ANTIBODY PEPTIDES
DE69634092D1 (de) Herstellung von antikörpern
ES2015654A6 (es) Un procedimiento para preparar anticuerpos anti-idiotipicos para antigeno asociado con melanoma, de alto peso molecular anti-humano.
ATE285418T1 (de) Humanisierter antikörper spezifisch für das oberflächenantigen pre-s1 von hbv und dessen präparation
IL187595A (en) Pharmaceutical preparation containing monoclonal antibody - tumors and production
CA2137280A1 (fr) Clonage du gene codant pour la proteine gp28.5 de toxoplasma gondii; fragments peptidiques de cette proteine et leurs applications
AU2911289A (en) Carcinoma-associated antigens, and antibodies which recognize these antigens
DE59209776D1 (de) Monoklonale Antikörper gegen tumorassoziierte Antigene, Verfahren zu ihrer Herstellung und ihre Verwendung
HUP0001270A2 (en) Compositions and methods for the treatment and diagnosis of breast cancer
GR890100333A (en) Antihuman antigen antibodies